The story of the erectile dysfunction drug presents a intricate picture for investors. While the initial release click here generated substantial gains, the end of its exclusive rights opened the door to cheaper competitors, dramatically eroding market share. This presents a particular challenge for firms depending on related blockbuster products,

The story of Viagra, and its creator copyright, presents a intriguing case study for investors. Initially a blockbuster drug, producing billions in revenue , its exclusivity period created a wave of lower-priced alternatives , significantly eroding its position . While some firms may try to capitalize on related treatments , the present landscape d